IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy

Journal of Hepatology

Volumn 54, Issue 6, 2011, Pages 1094-1101

  Abe, Hiromi ^a,b,c   Hayes, C Nelson ^a,b,c   Ochi, Hidenori ^a,b,c   Maekawa, Toshiro ^a,b   Tsuge, Masataka ^c   Miki, Daiki ^a,b,c   Mitsui, Fukiko ^a,b,c   Hiraga, Nobuhiko ^a,b,c   Imamura, Michio ^a,b,c   Takahashi, Shoichi ^a,b,c   Kubo, Michiaki ^a   Nakamura, Yusuke ^a,d   Chayama, Kazuaki ^a,b,c  

^a RIKEN   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

IL28; ISG15; Liver biopsy; MxA; Single nucleotide polymorphism

Indexed keywords

2',5' OLIGONUCLEOTIDE SYNTHETASE; DOUBLE STRANDED RNA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERFERON REGULATORY FACTOR; INTERLEUKIN 28; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN A; PEGINTERFERON ALPHA2B; PROTEIN ISG15; RIBAVIRIN; RNA LIGASE; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIVER; LIVER BIOPSY; LIVER CELL; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

2',5'-OLIGOADENYLATE SYNTHETASE; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CYTOKINES; DRUG THERAPY, COMBINATION; EIF-2 KINASE; FEMALE; GENE EXPRESSION; GTP-BINDING PROTEINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN; RNA, MESSENGER; TREATMENT OUTCOME; UBIQUITINS;

EID: 79956147625     PISSN: 01688278     EISSN: 01688278     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.09.019     Document Type: Article

References (34)

1. J.M. Barrera, M. Bruguera, M.G. Ercilla, C. Gil, R. Celis, and M.P. Gil Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C Hepatology 21 1995 639 644
2. L.B. Seeff Natural history of chronic hepatitis C Hepatology 36 2002 S35 46
3. S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, and P. Marcellin Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
4. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
5. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
6. S. Zeuzem, J.M. Pawlotsky, E. Lukasiewicz, M. von Wagner, I. Goulis, and Y. Lurie International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C J Hepatol 43 2005 250 257 (Pubitemid 40956877)
7. D.M. Jensen, P. Marcellin, B. Freilich, P. Andreone, A. Di Bisceglie, and C.E. Brandao-Mello Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial Ann Intern Med 150 2009 528 540
8. N. Akuta, F. Suzuki, Y. Kawamura, H. Yatsuji, H. Sezaki, and Y. Suzuki Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels J Hepatol 46 2007 403 410 (Pubitemid 46185701)
9. N. Akuta, F. Suzuki, H. Sezaki, Y. Suzuki, T. Hosaka, and T. Someya Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load J Med Virol 78 2006 83 90 (Pubitemid 41783847)
10. N. Enomoto, I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, and C. Yamamoto Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection N Engl J Med 334 1996 77 81 (Pubitemid 26017933)
11. N. Enomoto, I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, and C. Yamamoto Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region J Clin Invest 96 1995 224 230
12. A. El-Shamy, M. Nagano-Fujii, N. Sasase, S. Imoto, S.R. Kim, and H. Hotta Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy Hepatology 48 2008 38 47 (Pubitemid 351975529)
13. T.M. Welzel, T.R. Morgan, H.L. Bonkovsky, D. Naishadham, R.M. Pfeiffer, and E.C. Wright Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial Hepatology 49 2009 1847 1858
14. S. Knapp, L.J. Yee, A.J. Frodsham, B.J. Hennig, S. Hellier, and L. Zhang Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR Genes Immun 4 2003 411 419 (Pubitemid 38967606)
15. M. Hijikata, Y. Ohta, and S. Mishiro Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon Intervirology 43 2000 124 127
16. M. Naito, A. Matsui, M. Inao, S. Nagoshi, M. Nagano, and N. Ito SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C J Gastroenterol 40 2005 381 388 (Pubitemid 40723929)
17. H. Tsukada, H. Ochi, T. Maekawa, H. Abe, Y. Fujimoto, and M. Tsuge A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C Gastroenterology 136 2009 1796 1805 e1796
18. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
19. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, and M.L. Abate IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
20. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, and N. Sakamoto Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
21. D.L. Thomas, C.L. Thio, M.P. Martin, Y. Qi, D. Ge, and C. O'Huigin Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
22. S.V. Kotenko, G. Gallagher, V.V. Baurin, A. Lewis-Antes, M. Shen, and N.K. Shah IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex Nat Immunol 4 2003 69 77 (Pubitemid 36109115)
23. P. Sheppard, W. Kindsvogel, W. Xu, K. Henderson, S. Schlutsmeyer, and T.E. Whitmore IL-28, IL-29 and their class II cytokine receptor IL-28R Nat Immunol 4 2003 63 68 (Pubitemid 36104710)
24. H.H. Gad, C. Dellgren, O.J. Hamming, S. Vends, S.R. Paludan, and R. Hartmann Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family J Biol Chem 284 2009 20869 20875
25. T. Marcello, A. Grakoui, G. Barba-Spaeth, E.S. Machlin, S.V. Kotenko, and M.R. MacDonald Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics Gastroenterology 131 2006 1887 1898 (Pubitemid 44958521)
26. M.D. Robek, B.S. Boyd, and F.V. Chisari Lambda interferon inhibits hepatitis B and C virus replication J Virol 79 2005 3851 3854 (Pubitemid 40327973)
27. N.E. Pagliaccetti, R. Eduardo, S.H. Kleinstein, X.J. Mu, P. Bandi, and M.D. Robek Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication J Biol Chem 283 2008 30079 30089
28. V.J. Desmet, M. Gerber, J.H. Hoofnagle, M. Manns, and P.J. Scheuer Classification of chronic hepatitis - diagnosis, grading and staging Hepatology 19 1994 1513 1520 (Pubitemid 24166476)
29. Y. Ohnishi, T. Tanaka, K. Ozaki, R. Yamada, H. Suzuki, and Y. Nakamura A high-throughput SNP typing system for genome-wide association studies J Hum Genet 46 2001 471 477 (Pubitemid 32744120)
30. A. Suzuki, R. Yamada, X. Chang, S. Tokuhiro, T. Sawada, and M. Suzuki Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis Nat Genet 34 2003 395 402 (Pubitemid 36935332)
31. Y. Mori, K. Moriishi, and Y. Matsuura Hepatitis C virus core protein: its coordinate roles with PA28gamma in metabolic abnormality and carcinogenicity in the liver Int J Biochem Cell Biol 40 2008 1437 1442
32. N. Kato, M. Hijikata, Y. Ootsuyama, M. Nakagawa, S. Ohkoshi, and T. Sugimura Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis Proc Natl Acad Sci USA 87 1990 9524 9528 (Pubitemid 120016475)
33. K.G. Moons, A.R. Donders, E.W. Steyerberg, and F.E. Harrell Penalized maximum likelihood estimation to directly adjust diagnostic and prognostic prediction models for overoptimism: a clinical example J Clin Epidemiol 57 2004 1262 1270 (Pubitemid 40023146)
34. M. Sarasin-Filipowicz, E.J. Oakeley, F.H. Duong, V. Christen, L. Terracciano, and W. Filipowicz Interferon signaling and treatment outcome in chronic hepatitis C Proc Natl Acad Sci USA 105 2008 7034 7039 (Pubitemid 351754525)